The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Dulaglutide (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms REWIND
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 19 Oct 2016 Planned End Date changed from 1 Apr 2019 to 1 Jul 2018.
- 19 Oct 2016 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2018.